固体瘤中调节性T细胞的选择性重编程可以强烈增强或抑制瘤生长
Rami Alfar1, John V Napoleon1, Imrul Shahriar1
1Department of Chemistry, Purdue Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Frontiers in immunology
|November 6, 2023
概括
研究人员使用一种新型的叶酸结合配体向调节性T细胞 (Tregs). 这种方法选择性地向瘤中的Tregs输送药物,显著减少瘤生长并改变免疫细胞表型,而不会产生全身毒性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 叶酸受体三角 (FRδ) 是调节性T细胞 (Tregs) 的生物标志物,尽管它不结合叶酸.
- 向瘤微环境中的Tregs是癌症免疫治疗的一个有前途的策略.
- 现有的免疫调节方法往往导致全身毒性.
研究的目的:
- 为了识别与FRδ结合的高亲缘性叶酸原体.
- 在小鼠瘤模型中,利用这种FRδ特异性联体对Tregs进行针对性的治疗剂的输送.
- 评估向Treg调节对瘤生长和免疫细胞透的影响.
主要方法:
- 用分子对接来识别具有与FRδ.高亲和力的叶酸原体.
- 特定于FRδ的配体与治疗药物 (托尔类受体7激动剂,甲) 结合.
- 对小鼠瘤异种移植中的Tregs进行向药物递送的评估,随后对瘤生长和免疫细胞表型进行分析.
主要成果:
- 针对Tregs的Toll-like受体7激素抑制了Treg标记物 (FOXP3,PD-1,CTLA4,HELIOS),减少了40-80%的瘤生长,并促进了炎症性免疫细胞表型.
- 向Tregs向德克萨米他增强了瘤生长,并将免疫细胞转移到抗炎性表型.
- 向药物没有与健康组织中的Tregs或免疫细胞结合,表明缺乏全身毒性.
结论:
- Tregs对瘤生长有显著的影响,即使在低频率 (<1%).
- 针对性地向瘤中的Tregs输送免疫调节药物可以有效地操纵Treg功能.
- 这种针对FRδ的方法为癌症治疗提供了一种具有减少全身副作用的策略.
相关概念视频
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


